Broad neutralization coverage of HIV by multiple highly potent antibodies
By L. Walker, M. Huber, K. Doores, Emilia Falkowska, R. Pejchal, J. Julien, Sheng-Kai Wang, Alejandra Ramos, P. Chan-Hui, M. Moyle and 13 more. Nature, 2011
1,548 citations recorded by the source corpus.
Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to treat or protect against global circulating viruses. Here we probed the neutralizing antibody repertoires of four human immunodeficiency virus (HIV)-infected donors with remarkably broad and potent neutralizing responses and rescued 17 new monoclonal antibodies that neutralize broadly across clades. Many of the new monoclonal antibodies are almost tenfold more potent than the recently described PG9, PG16 and VRC01 broadly neutralizing monoclonal antibodies and 100-fold more potent than the original prototype HIV broadly neutralizing monoclonal antibodies. The monoclonal antibodies largely recapitulate the neutralization breadth found in the corresponding donor serum and many recognize novel epitopes on envelope (Env) glycoprotein gp120, illuminating new targets for vaccine design. Analysis of neutralization by the full complement of anti-HIV broadly neutralizing monoclonal antibodies now available reveals that certain combinations of antibodies should offer markedly more favourable coverage of the enormous diversity of global circulating viruses than others and these combinations might be sought in active or passive immunization regimes. Overall, the isolation of multiple HIV broadly neutralizing monoclonal antibodies from several donors that, in aggregate, provide broad coverage at low concentrations is a highly positive indicator for the eventual design of an effective antibody-based HIV vaccine.
Subfields: Hepatology, Infectious Diseases, Virology
View Paper: https://www.semanticscholar.org/paper/d2723e5394a680a8e1cd22514c966c67f67a1f5e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Infectious Diseases
In Virology
Citations in the corpus
- Mucosal Immunity in the Female Genital Tract, HIV/AIDS (2014, background): “Most HIV-1 vaccination strategies aim to induce human HIV-specific antibodies able to inhibit the infection of target cells at the onset of viral transmission; however, inducing such bNAbs by vaccination is likely to be very difficult [73–75].”
- A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies (2013, background): “trimer stability, the deletion of the MPER to improve homogeneity and solubility, and the introduction of a T332N substitution to create the epitopes for several bNAbs that depend on the presence of this glycan [5,6,24,30,31].”
- Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys (2013, positive): “We focused on the N332 glycan-dependent mAb PGT121 10 and the CD4 binding site-specific mAbs 3BNC117 6 and b12 20 .”
- Biological roles of glycans (2016, background): “Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by specific antibodies, such as that seen on the surface of the HIV virion (507) (508) (509) 594) .”
- A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations (2020, background): “HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.”
- IDEPI: Rapid Prediction of HIV-1 Antibody Epitopes and Other Phenotypic Features from Sequence Data Using a Flexible Machine Learning Platform (2014, background): “By definition, a bNab is able to neutralize (in experimental assays) a large proportion of reference viruses (e.g. [38–40]).”